Egetis Therapeutics AB (publ)

Stockholm Stock Exchange EGTX.ST

Egetis Therapeutics AB (publ) Free Cash Flow Yield on January 14, 2025: -14.57%

Egetis Therapeutics AB (publ) Free Cash Flow Yield is -14.57% on January 14, 2025, a -8.45% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Egetis Therapeutics AB (publ) 52-week high Free Cash Flow Yield is -8.77% on June 10, 2024, which is 39.82% above the current Free Cash Flow Yield.
Egetis Therapeutics AB (publ) 52-week low Free Cash Flow Yield is -20.34% on November 06, 2024, which is -39.59% below the current Free Cash Flow Yield.
Egetis Therapeutics AB (publ) average Free Cash Flow Yield for the last 52 weeks is -14.16%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: EGTX.ST

Egetis Therapeutics AB (publ)

CEO	Mr. Nicklas Westerholm
IPO Date	April 7, 2011
Location	Sweden
Headquarters	Klara Norra Kyrkogata 26
Employees	28
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Key trends

Past 5 years